Exelon Guides FY26 Adj. EPS In Line With Estimates

Exelon initiated 2026 adjusted operating earnings guidance of $2.81–$2.91 per share (street average $2.83) and reaffirmed an operating earnings CAGR target of 5–7% for 2025–2029. The board declared a $0.42 quarterly dividend payable March 13, 2026, while management highlighted a $41.3 billion four-year capital plan and 7.9% rate base growth as the rationale for near-top-end annualized earnings growth; EXC traded up roughly 1.24% pre-market to $45.00.

Analysis

Market structure: Exelon (EXC) benefits directly from a $41.3B four-year capital plan and guided 5–7% CAGR (2025–29), implying ~7.9% rate‑base growth that favors regulated generation/utility contractors, grid equipment suppliers, and investment-grade utility credit markets. Winners: EXC equity, regulated utility suppliers, muni/IG underwriters; losers: merchant power generators and pure-play renewables exposed to wholesale price volatility. The dividend ($0.42/qtr → ~3.7% yield at $45) supports income-sensitive flows and should stabilize equity relative to cyclicals over 12–36 months.

Risk assessment: Key tail risks are regulatory disallowance or adverse state rate-case outcomes, material nuclear outages, or a sustained 150–200bp rise in real yields compressing utility valuations and triggering rating downgrades. Near-term (days–weeks) sensitivity is to market sentiment and rate moves; medium-term (months) hinges on rate-case approvals and capex execution; long-term (years) depends on regulated ROE resets and realized capex returns. Hidden dependencies include pension funding, decommissioning liabilities, and availability of tax incentives that can materially swing FCF.

Trade implications: Favor a constructive bias on EXC with capital deployment sized to risk budget: buy on dips under $42 and add toward $38, trim into strength above $55–60; consider funded LEAPS to capture 2029 growth. Pair trade: long EXC vs short NEE (NextEra) to express regulated, rate‑base growth over merchant/renewable build risk; target spread sizing 1:1 and monitor RTO price signals. Options: sell cash‑secured $40 puts (30–60d) if premium >3% and buy Jan 2028 $55 calls to leverage the multi‑year CAGR thesis.

Contrarian angles: Consensus assumes smooth capex execution and stable ROEs; markets underprice a scenario where higher rates force slower equity compounding and tighter ROEs—this would compress EXC by >20%. Conversely, successful rate-case wins and low capex overruns could justify a 15–25% upside by 2027. Watch regulatory filings and state PSC decisions over the next 90–180 days; a string of approvals is a catalyst, while any major nuclear outage or negative PSC signal is a fast-exit trigger.

Key Decisions for Investors

• Establish a 2–3% long position in EXC equity (ticker EXC) over the next 2–6 weeks; add on pullbacks under $42 and target trimming at $55–60 (realize ~20–35% upside).
• Implement a paired relative trade: go long EXC (2% notional) and short NEE (2% notional) to express regulated rate‑base growth vs merchant/renewable execution risk; rebalance monthly and widen stop if spread moves >10% against position.
• Sell cash‑secured EXC $40 puts with 30–60 day expiries if premium >3% (collect yield, effective buy below $40) and size to a max assignment risk of 3% portfolio.
• Buy EXC Jan 2028 $55 LEAPS (or equivalent delta 0.40–0.55) sized 1–1.5% notional to capture multi‑year CAGR; hedge 25–50% of position by selling near‑dated calls if IV rises >30% post‑earnings.
• Monitor state Public Service Commission rate‑case outcomes and any nuclear outage reports over the next 90–180 days; if two or more major approvals occur, increase exposure by 50%; if a major adverse ruling or a >200bp sustained rise in real yields occurs, reduce equity exposure to zero.